Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Brickell Biotech Inc (BBI)

Brickell Biotech Inc (BBI)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 47,477
  • Shares Outstanding, K 71,945
  • Annual Sales, $ 1,820 K
  • Annual Income, $ -20,910 K
  • 60-Month Beta 0.20
  • Price/Sales 26.12
  • Price/Cash Flow N/A
  • Price/Book 1.42
Trade BBI with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.88
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 08/11/21
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/21
See More
  • Average Estimate -0.11
  • Number of Estimates 1
  • High Estimate -0.11
  • Low Estimate -0.11
  • Prior Year -0.43
  • Growth Rate Est. (year over year) +74.42%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.5920 +8.77%
on 07/20/21
1.0400 -38.09%
on 06/30/21
-0.2255 (-25.94%)
since 06/23/21
3-Month
0.5920 +8.77%
on 07/20/21
1.0900 -40.93%
on 04/29/21
-0.2866 (-30.80%)
since 04/23/21
52-Week
0.4660 +38.18%
on 11/04/20
1.7000 -62.12%
on 02/11/21
-0.2941 (-31.35%)
since 07/23/20

Most Recent Stories

More News
Brickell Biotech Announces Closing of $8.05 Million Bought Deal Offering of Common Stock, Including Full Exercise of the Underwriter's Option to Purchase Additional Shares

Brickell Biotech, Inc. (Nasdaq: BBI) (the "Company" or "Brickell"), a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescription therapeutics for the treatment...

BBI : 0.6439 (-2.42%)
Brickell Biotech Increases Previously Announced Bought Deal Offering of Common Stock to $7.0 Million

Brickell Biotech, Inc. (Nasdaq: BBI) (the "Company" or "Brickell"), clinical-stage pharmaceutical company focused on developing innovative and differentiated prescription therapeutics for the treatment...

BBI : 0.6439 (-2.42%)
Brickell Biotech Announces $5.0 Million Bought Deal Offering of Common Stock

Brickell Biotech, Inc. (Nasdaq: BBI) ("Brickell" or the "Company"), a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescription therapeutics for the treatment...

BBI : 0.6439 (-2.42%)
Brickell Biotech to Participate at William Blair's Biotech Focus Conference 2021

Brickell Biotech, Inc. ("Brickell") (Nasdaq: BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescription therapeutics for the treatment of debilitating...

BBI : 0.6439 (-2.42%)
Thinking about buying stock in Vertex Energy, Exela Technologies, Bridgeline Digital, Verb Technology, or Brickell Biotech?

/PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for VTNR, XELA, BLIN, VERB, and BBI.

BLIN : 5.45 (-9.32%)
VTNR : 8.55 (-4.36%)
XELA : 2.43 (-6.90%)
BBI : 0.6439 (-2.42%)
VERB : 2.49 (+5.51%)
Brickell Biotech Announces Final Patient Completed in First U.S. Phase 3 Pivotal Clinical Study and Patient Enrollment Completed in Second U.S. Phase 3 Pivotal Clinical Study of Sofpironium Bromide Gel, 15% for the Treatment of Primary Axillary Hyperhidrosis

Brickell Biotech, Inc. ("Brickell" or the "Company") (Nasdaq: BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescription therapeutics for the treatment...

BBI : 0.6439 (-2.42%)
Brickell Biotech Announces Initiation of a Phase 1 Study of Sofpironium Bromide Gel in Primary Palmoplantar Hyperhidrosis Patients by its Development Partner, Kaken Pharmaceutical in Japan

Brickell Biotech, Inc. ("Brickell" or the "Company") (Nasdaq: BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescription therapeutics for the treatment...

BBI : 0.6439 (-2.42%)
Brickell Biotech Announces Publication of Japan Phase 3 Long-Term Safety and Efficacy Study Results for Sofpironium Bromide Gel, 5% (ECCLOCK(R)) in the Journal of Dermatology

Brickell Biotech, Inc. ("Brickell") (Nasdaq: BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescription therapeutics for the treatment of debilitating...

BBI : 0.6439 (-2.42%)
Brickell (BBI) Reports Q1 Loss, Lags Revenue Estimates

Brickell (BBI) delivered earnings and revenue surprises of -25.00% and -83.00%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

BBI : 0.6439 (-2.42%)
Brickell Biotech Reports First Quarter 2021 Financial Results and Provides Corporate Update

Completed enrollment in Phase 3 pivotal Cardigan I study and exceeded 70% enrollment in Phase 3 pivotal Cardigan II study

BBI : 0.6439 (-2.42%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Strengthening short term outlook on maintaining the current direction.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Business Summary

Brickell Biotech, Inc. is a clinical-stage pharmaceutical company. It is focused on developing prescription therapeutics for treatment of skin diseases. The company's pipeline consists of therapeutics for hyperhidrosis, cutaneous T-cell lymphoma, psoriasis, and other prevalent severe skin diseases. ...

See More

Key Turning Points

3rd Resistance Point 0.6959
2nd Resistance Point 0.6840
1st Resistance Point 0.6639
Last Price 0.6439
1st Support Level 0.6319
2nd Support Level 0.6200
3rd Support Level 0.5999

See More

52-Week High 1.7000
Fibonacci 61.8% 1.2286
Fibonacci 50% 1.0830
Fibonacci 38.2% 0.9374
Last Price 0.6439
52-Week Low 0.4660

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar